Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Antigen engineering in DNA immunization.

Lu S, Manning S, Arthos J.

Methods Mol Med. 2000;29:355-74. doi: 10.1385/1-59259-688-6:355.

PMID:
21374335
2.

The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague.

Sebbane F, Jarrett C, Gardner D, Long D, Hinnebusch BJ.

Infect Immun. 2009 Mar;77(3):1222-9. doi: 10.1128/IAI.00950-08. Epub 2008 Dec 22.

3.

DNA vaccines: ready for prime time?

Kutzler MA, Weiner DB.

Nat Rev Genet. 2008 Oct;9(10):776-88. doi: 10.1038/nrg2432. Review.

4.

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.

Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S.

Vaccine. 2008 Jul 23;26(31):3947-57.

5.

Immunogenicity of DNA vaccines in humans: it takes two to tango.

Lu S.

Hum Vaccin. 2008 Nov-Dec;4(6):449-52. Epub 2008 Nov 28. Review.

PMID:
18443427
6.

The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods.

Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S.

Vaccine. 2008 Apr 16;26(17):2100-10. doi: 10.1016/j.vaccine.2008.02.033. Epub 2008 Mar 6.

7.

Current progress of DNA vaccine studies in humans.

Lu S, Wang S, Grimes-Serrano JM.

Expert Rev Vaccines. 2008 Mar;7(2):175-91. doi: 10.1586/14760584.7.2.175. Review.

PMID:
18324888
8.

Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice.

Wang S, Joshi S, Mboudjeka I, Liu F, Ling T, Goguen JD, Lu S.

Vaccine. 2008 Mar 20;26(13):1664-74. doi: 10.1016/j.vaccine.2008.01.024. Epub 2008 Feb 4.

9.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.

J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331. Epub 2008 Jan 14.

11.

Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.

Herrmann JE, Wang S, Zhang C, Panchal RG, Bavari S, Lyons CR, Lovchik JA, Golding B, Shiloach J, Lu S.

Vaccine. 2006 Jul 26;24(31-32):5872-80. Epub 2006 May 15.

PMID:
16790303
12.

Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine.

Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S.

Vaccine. 2006 May 22;24(21):4531-40. Epub 2005 Aug 18.

PMID:
16140431
13.

Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Glynn A, Roy CJ, Powell BS, Adamovicz JJ, Freytag LC, Clements JD.

Infect Immun. 2005 Aug;73(8):5256-61.

14.

Immunization of mice with YscF provides protection from Yersinia pestis infections.

Matson JS, Durick KA, Bradley DS, Nilles ML.

BMC Microbiol. 2005 Jun 24;5:38.

15.

Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague.

Swietnicki W, Powell BS, Goodin J.

Protein Expr Purif. 2005 Jul;42(1):166-72. Epub 2005 Mar 17.

PMID:
15939303
16.

Human immune response to a plague vaccine comprising recombinant F1 and V antigens.

Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M.

Infect Immun. 2005 Jun;73(6):3598-608.

17.

Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens.

Glynn A, Freytag LC, Clements JD.

Vaccine. 2005 Mar 14;23(16):1957-65.

PMID:
15734068
18.
19.
20.

A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.

Wang S, Heilman D, Liu F, Giehl T, Joshi S, Huang X, Chou TH, Goguen J, Lu S.

Vaccine. 2004 Sep 3;22(25-26):3348-57.

PMID:
15308359
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk